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Organ-specific differences in epidermal growth factor receptor (EGFR) mutational spectra and frequencies were found in lung cancer
and sporadic and BRCA1/2-related breast cancers. Additionally, we found a high frequency of EGFR mutations in the tumour stroma
of these invasive breast carcinomas. Those organ-specific mutational spectra and potential targets in the cancer-associated stroma
might influence the efficacy of TKI therapy.
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The most common cancers worldwide are lung and breast cancer,
accounting for over 2 million new cases each year. Approximately
3 years ago, molecular targeted therapy, starting with the
introduction of imatinib, which targets the tyrosine kinases (TK)
BCR–ABL, KIT and PDGFR, for the treatment of chronic myeloid
leukaemia, was anticipated to provide a new approach to fight
malignancies. In clinical trials, the response to epidermal growth
factor receptor (EGFR) inhibitors, such as gefitinib, has varied
widely, ranging from rare in breast cancers to 10–30% in
metastatic non-small-cell lung carcinoma (NSCLC) (Dancey and
Freidlin, 2003). Recently, somatic mutations in the TK domain of
the EGFR gene have been identified in the NSCLC of the patients
who showed increased response to gefitinib, suggesting clinical
utility as a predictive factor (Lynch et al, 2004; Paez et al, 2004).
Despite the promising response in a subset of NSCLC, other solid
tumours, such as breast cancer, do not share this. We hypothesised
that differences in EGFR somatic mutational spectra and
frequencies among the different solid tumours may result in
different responsiveness. Thus, we sought to determine and
compare the mutational frequencies and spectra in NSCLC and
breast carcinomas. In addition, regarding the growing under-
standing of the tumour–stroma interaction and the possible role
of cancer-associated mesenchyme as a novel target for anticancer
therapy, we also analysed the stroma of invasive breast adeno-
carcinomas for EGFR mutations.
MATERIALS AND METHODS
The TK domain of EGFR, encoded by exons 18–21, was directly
sequenced in 60 NSCLC samples, 48 samples of sporadic breast
carcinoma and 24 samples from hereditary breast cancers (17 with
BRCA1 mutations and seven with BRCA2 mutations, respectively).
All samples were obtained as anonymised archival material under
approval from the respective Institutional Review Boards.
DNA extraction and mutation analysis
In the breast cancer samples, tumour epithelial and stromal
components were collected separately with laser-capture micro-
dissection (LCM). For NSCLC, tumour-enriched paraffin-em-
bedded samples have been used. Genomic DNA was extracted by
proteinase K digestion as described by us previously (Fukino et al,
2004). We directly sequenced exons 18–21 of the TK domain in the
EGFR gene with the primers listed below. PCR consisted of 40
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scycles using an annealing temperature of 551Ci na1 5ml reaction
mixture containing 7.5ml HotStar MasterMix, 1.5ml 5xQ-Solution
(Invitrogen, Carlsbad, CA, USA) and 0.25ml of each primer. PCR
products were then sequenced using Big Dye v3.1 terminator
technology and the ABI 3730 analyzer (Applied Biosystems,
Perkin-Elmer Corp., Norwalk, CT, USA) according to the
manufacturer’s recommendation for mutation analysis (supple-
ments 1 and 2).
We used two-sided Fisher exact test to evaluate differences
between groups.
Primers for mutation analysis were as follows: exon 18 – GCT
GAGGTGACCCTTGTCTC (sense), ACAGCTTGCAAGGACTCTGG
(antisense); exon 19 – CATGTGGCACCATCTCACA (sense),
CAGCTGCCAGACATGAGAAA (antisense); exon 20 – CACA
CTGACGTGGCCTCTCC (sense), TATCTCCCCTCCCCGTATCT
(antisense); exon 21 – CCTCACAGCAGGGTCTTCTC (sense),
CCTGGTGTCAGGAAAATGCT (antisense).
RESULTS
In two (3.3%) of the 60 NSCLC samples, somatic in-frame deletions
were detected in exon 19 (Table 1, Figure 1). Both samples showed
a heterozygous in-frame deletion of five amino acids (E, L, R, E, A)
(delE746-A750) through loss of nucleotides 2235–2249 and 2236–
2250, respectively. These two deletions coincided with those
reported in the previous reports, suggesting gefitinib responsive-
ness (Lynch et al, 2004; Paez et al, 2004).
In total, seven somatic missense mutations were detected in
seven (14.6%) of 48 sporadic breast cancer samples. No correlation
was detected between tumour grade and mutation status. We
identified 14 missense mutations in 11 (45.8%) of 24 breast cancers
from BRCA1/2 mutation carriers (Figures 1 and 2, Table 1). Thus,
the frequency of EGFR mutations was significantly higher in
BRCA1/2-related breast cancers compared to that in sporadic ones
(P¼0.0079). In addition, three silent mutations that did not alter
the amino acid were identified in three hereditary breast cancer
samples, of which two also harboured other missense mutations.
There was no difference in the frequency of EGFR mutations
between BRCA1- (eight out of 17, 47%) and BRCA2- (three out of
seven, 43%) related breast cancers (P¼1.0). It is noteworthy that,
among the 11 BRCA1/2-related breast cancers with EGFR somatic
mutations, eight (72.7%) were located exclusively in the stroma
(Table 2, Figure 1). Similarly, of the seven sporadic breast cancers
with somatic EGFR mutations, four (57.1%) had mutations only in
the stroma (Table 2, Figures 1 and 2). Furthermore, 57% (eight out
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Figure 1 Spectra of somatic EGFR mutations. Location of somatic mutations found in 60 NSCLC, 48 sporadic and 24 hereditary (BRCA1/2 mutation
positive) breast cancers. Exons are shown as bars with intronic regions as lines. For breast cancer samples, labels above each bar/line indicate mutations in
the stroma, and labels below denote mutations found in neoplastic epithelium. Green labels indicate silent variants.
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sof 14 hereditary, four out of seven sporadic) of all mutations were
located in exon 20. In addition, we identified 10 somatic intronic
single-nucleotide variants (ISNV) in seven of 24 (29.2%) hereditary
breast cancers and nine ISNV in seven out of 48 (14.6%) sporadic
breast cancers. Finally, nonsense mutations were identified in
one hereditary breast cancer and two sporadic breast cancers. No
Table 1 Spectra of EGFR somatic mutations identified in exons 18–21 among 60 NSCLC samples, 48 sporadic breast cancers and 24 hereditary breast
cancers
Mutation Subdomain Her2-neu
Non-small cell lung cancer (n¼60)
Sample L1 Deletion of 15 nucleotides at codons 746–750 Nucleotide 2235–2249 II NA
Sample L2 Deletion of 15 nucleotides at codons 746–750 Nucleotide 2236–2250 II NA
Sporadic breast cancer (n¼48)
Stroma
Sample S1 T693A ACA–GCA I (L718) neg.
IVS 18+19 (g/a)
Sample S2 IVS 18+2 (t/a) neg.
Sample S3 A698T GCT–ACT I (L718) neg.
F712F TTC–TTT I (L718)
Sample S4 IVS 18 1 (g/a) neg.
Sample S5 IVS 18 4 (c/t) neg.
Sample S6 IVS 18+6 (g/a) neg.
IVS 18+25 (g/a) neg.
Sample S7* E762K GAA–AAA III (E762) pos.
Sample S8 G810D GGC–GAC VI (G824) neg.
Sample S9 Y827Stop TAC–TAA VI (Y827) pos.
Sample S10 IVS 19+53 (c/t) neg.
Sample S11 IVS 20+6 (c/t) pos.
Epithelium
Sample S6 IVS 20+6 (c/t) neg.
Sample S12 E709K GAA–AAA I (L718) neg.
Sample S13 S768N AGC–AAC IV (V774) NA
W817Stop TGG–TAG VI (G824)
Sample S14 R776L CGC–CTC IV (V774) pos.
BRCA-related breast cancer (n¼24)
Stroma
Sample H1 Q791R CAG–CGG V NA
L816P CTC–CCC VI (G824)
Sample H2 L792F CTC–CTT V NA
D761N GAT–AAT III (E762)
IVS 19–15(t/c)
Sample H3 Q821R CAG–CGG VI (G824) neg.
Sample H4 N756S AAC–AGC III (E762) NA
F795F TTC–TTT V
Sample H5 V742A GTC–GCC II (A743) NA
Sample H6* N842S AAC–AGC VI (N842) neg.
Sample H7 Q821Stop CAG–TAG VI (G824) NA
V819A GTG–GCG VI (G824)
Sample H8 V742A GTC–GCC II (A743) neg.
Sample H16 IVS 19–3(t/c) NA
Epithelium
Sample H5 IVS 20+14 (g/a) NA
IVS 19+5 (g/a)
Sample H7 I759I ATC–ATT III (E762) NA
Sample H9 Q791R CAG–GG VI (Y827) neg.
Sample H10 Q791R CAG–CGG V pos.
I822T ATC–ACC VI (G824)
IVS 18+19 (g/a)
IVS 20+14 (g/a)
Sample H11 R748R AGA–AGG II (L747) neg.
Sample H12* G724S GGC–AGC I (G724) NA
Sample H13 IVS 19–10 (t/c) neg.
IVS 20+14 (g/a)
Sample H14 IVS 19–14 (t/c) NA
Sample H15 IVS 20+14 (g/a) NA
For breast cancers, both the surrounding stroma and tumour epithelium have been analysed separately (see also Figure 2). Column 2 shows affected codon with amino-acid
change and corresponding base change in column 3. Column 4 indicates the corresponding TK subdomain with the closest highly conserved residue in parentheses. Her2-neu
expression status is given in column 5. Samples that display a mutation in one of the highly conserved amino-acid residues are indicated by asterisk.
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sin-frame deletions as reported for NSCLC were identified in either
hereditary or sporadic breast cancer samples.
DISCUSSION
Our data show that EGFR mutations occur at a significantly higher
frequency in hereditary breast cancer compared to sporadic breast
cancer (P¼0.0079). This may not be surprising given the
functional effect of BRCA1/2 mutations: defects in BRCA1 and
BRCA2 have been shown to disrupt the DNA repair mechanism,
which leads to genomic instability. Despite the difference in
mutation frequencies between sporadic and hereditary breast
cancers, it is obvious that sporadic and heritable breast cancers
both have a similarly high frequency of EGFR mutations in tumour
stroma, and that the majority of missense mutations lie in exon 20,
in contrast to those in NSCLC.
The mutations reported in gefitinib-sensitive NSCLC were
located in the TK domain encoded by exons 18–21, and have
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Figure 2 Somatic EGFR mutations in the epithelium or stroma of sporadic and hereditary breast carcinomas. Each of the four columns (A–D, E–H, I–L
and M–P) represents one EGFR mutation-positive sample and the corresponding images taken during the LCM process. The sample codes corresponding
to Table 1 are indicated below each set of chromatograms. Each set of chromatograms (A, E, I and M) shows the control (wild-type) sequence in the top
row, followed by the sequence of the mutation-negative compartment. The heterozygous mutation and surrounding sequences are shown in forward (f) and
reverse (r) directions in the bottom two rows. The first column shows sample H2, harbouring a somatic D761N mutation in the tumour epithelium (A, f and
r) but not tumour stroma (mut. neg. in A). Image (B) shows an overview of this tumour (H&E,  100 and  200) and images (C) and (D) confirm that we
accurately captured stroma (C) and epithelium (D). The second column shows the chromatograms (E) and tissue image (F) of sample H9, harbouring the
somatic Q791R mutation in the stroma (f and r in (E)) but not epithelium (E, mut. neg.). The corresponding images (G) and (H) depict the captured
epithelium (G) and the tissue image after extraction of the epithelial component by LCM (H). The third column represents the sporadic breast
adenocarcinoma sample S1 (J) with a somatic T693A mutation in the stromal compartment (I, f and r) but not epithelium (mut. neg. in (I)). Again, images
(K) and (L) verify the separation of tumour epithelium (L) and stroma (K). The last column shows sample S13 harbouring a W817X mutation in the
tumour epithelium (M, f and r) but not stroma (M, mut. neg.). The neoplastic epithelium is microdissected (O) out of the whole tumour section (N), leaving
the stromal compartment (P).
Table 2 Frequencies of EGFR mutations presented separately for
neoplastic epithelium and the tumour stromal compartment from each
case
Epithelium Stroma
NSCLC (n¼60) 2 (3.3%) Not done
Sporadic BC (n¼48) 3 (6.3%) 4 (8.3%)
Hereditary BC (n¼24) 3 (12.5%) 8 (33.3%)
NSCLC¼non-small-cell-lung cancer; BC¼breast adenocarcinoma. For NSCLC
samples, the tumour stroma was not analysed separately.
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sbeen shown to increase growth factor signalling and confer
susceptibility to gefitinib in vitro (Lynch et al, 2004; Paez et al,
2004). These data suggest that the clinical outcome after molecular
targeted therapy strongly depends on acquired alterations in target
genes, and, by extrapolation, perhaps germline alterations (host
risk) and/or functional status of the molecular target as well. At
this point, we can only speculate on the functional properties that
the mutations described in our breast cancers will have on EGFR
receptor signalling. The majority of variants identified lie in close
proximity to the highly conserved amino-acid residues within the
TK domain I to VI (Table 1). Extrapolating from other reports, it
seams likely that these could affect the ATP-binding pocket and
result in gain of function (Huang et al, 2004). Truncating
mutations such as the nonsense mutations found in breast cancers
are predicted to result in loss of function, and, by extrapolation
from a recent report by Huang et al (2004) lack of responsiveness
to EGFR-TKI’s. Since the samples have been obtained as
anonymised material, we are not able to link our results to the
outcome of possible EGFR-directed therapy. Her2-neu expression
is reported to be associated with responsiveness to therapy,
especially in tamoxifen-resistant cases and it is suggested that the
heterodimerisation of EGFR/Her2-neu might contribute. Based on
our data, we did not find any evidence for a correlation between
EGFR mutation status and Her2-neu expression (Table 1).
What the effect of EGFR mutations as possible targets for
anticancer therapy, in the stroma on responsiveness to EGFR-
TKI’s, is unknown. Given our and other existing data on the
tumour microenvironment (Dancey and Freidlin, 2003; Fukino
et al, 2004), it may be postulated that the high frequencies of
stromal EGFR mutations in sporadic and hereditary breast cancers
could confound responsiveness to EGFR-TKI and may help explain
interpatient variation. Thus, we suggest that future clinical trials
employing molecular targeted therapy evaluate these genetic
factors, not only in the traditional epithelial neoplasm but also
in the surrounding tumour stroma in order to establish their role
in and predictive value for interindividual variation in responses.
In summary, we have shown that EGFR mutations are found in a
distinct, organ-specific pattern, and suggest that mutational
spectra may be only one basis for prediction of response to
EGFR-TKI’s. Furthermore, we have demonstrated that the tumour
stroma was rich in EGFR gene alterations compared to the
epithelium. We previously reported on a model of tumour–
microenviroment interaction in multistep breast carcinogenesis
and pointed out the importance of mutations found exclusively in
the tumour stroma (Kurose et al, 2001, 2002). It is acknowledged
that the stroma can modulate the neoplastic epithelium by
mediating invasion and progression. Therefore, it is possible that
any EGFR-TK-directed therapy should consider anticancer targets
in the tumour stroma as well as neoplastic epithelium, and, indeed,
perhaps such TK-directed therapy in breast cancer will predomi-
nantly affect this tumour–microenvironment interaction by
inhibiting invasion and progression rather than influence tumour
mass.
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